Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PHIO PHARMACEUTICALS CORP.

(PHIO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Phio Pharmaceuticals Presents New in Vivo Data At the 2021 Asco Annual Meeting Showing Dual-Targeting Intasyl Offers Increased Efficacy and Safety Potential over Other Therapeutic Approaches

06/04/2021 | 08:00am EDT

Phio Pharmaceuticals Corp. announced positive in vivo data that provide further evidence on the utility of its INTASYL™ self-delivering RNAi therapy platform in the field of immuno-oncology. The new study data show how INTASYL can be easily deployed to target multiple proteins and provide evidence of the synergy of the Company's pipeline products. In the study, INTASYL specifically dual-targeting BRD4 and PD-1 elicited complete tumor responses in an in vivo hepatoma model, and significantly outperformed the efficacy of small molecule and antibody treatments towards the same targets. In this study, the Company assessed the efficacy of mouse/human BRD4-targeting INTASYL PH-894 as monotherapy or co-formulated with mouse PD-1 targeting INTASYL mPH-762, in treating a subcutaneous Hepa1-6 model of murine hepatoma in C57BL/6N mice. Positive controls included JQ-1, a small molecule inhibitor of BRD4 and anti-mouse PD-1 monoclonal antibody (mAb) or both treatments.


ę S&P Capital IQ 2021
All news about PHIO PHARMACEUTICALS CORP.
09/16US Stocks Mostly Lower Thursday After Surprise Retail Sales Gain, Rise in Jobless Claim..
MT
09/16US Stocks End Mostly Lower as Investors Weigh Surprise Retail Sales Gain Against Rising..
MT
09/16Health Care Stocks Largely Sitting Out Markets Recovery This Afternoon
MT
09/16Health Care Stocks Muted in Premarket Thursday
MT
09/16PHIO PHARMACEUTICALS : Presents Data at ESMO 2021 Demonstrating Persistent Anti-Tumor Immu..
PR
09/16Phio Pharmaceuticals Presents Data at ESMO 2021 Demonstrating Persistent Anti-Tumor Imm..
CI
09/10PHIO PHARMACEUTICALS : HCW 23rd Annual Global Investment Conference Presentation
PU
09/06PHIO PHARMACEUTICALS : to Participate in the H.C. Wainwright 23rd Annual Global Investment..
AQ
09/03PHIO PHARMACEUTICALS : to Participate in the H.C. Wainwright 23rd Annual Global Investment..
PR
08/31PHIO PHARMACEUTICALS : Announces Upcoming Data Presentation at the ESMO Virtual Congress 2..
PR
More news
Analyst Recommendations on PHIO PHARMACEUTICALS CORP.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -14,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,95x
Yield 2021 -
Capitalization 29,1 M 29,1 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 0,58x
Nbr of Employees 10
Free-Float 99,7%
Chart PHIO PHARMACEUTICALS CORP.
Duration : Period :
Phio Pharmaceuticals Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PHIO PHARMACEUTICALS CORP.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 2,15 $
Average target price 6,00 $
Spread / Average Target 179%
EPS Revisions
Managers and Directors
Gerrit Dispersyn President, Chief Executive Officer & Director
Caitlin Kontulis Secretary, VP-Finance & Administration
Robert J. Bitterman Chairman
Simon Fricker Vice President-Research
James Cardia Vice President-Business Operations
Sector and Competitors
1st jan.Capi. (M$)
PHIO PHARMACEUTICALS CORP.-20.07%29
MODERNA, INC.311.74%173 624
LONZA GROUP AG30.56%59 611
IQVIA HOLDINGS INC.46.01%50 128
CELLTRION, INC.-23.54%31 745
SEAGEN INC.-7.88%29 353